Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm
Wenwen Guo1,2, Yigeng Cao1,2, Jia Liu1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Bone Marrow Transplantation
|July 20, 2023
Abstract
No abstract available in PubMed .
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.3K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.4K
